Business Context and Reporting Period
This Form 8-K is filed by NanoVibronix, Inc. (trading symbol: NAOV) on November 19, 2024. The filing addresses a critical corporate governance issue regarding the company's continued listing on the Nasdaq Capital Market. Note: The request metadata referenced "Envue Medical, Inc.", but the source text explicitly identifies the registrant as NanoVibronix, Inc.
Key Financial Metrics
The filing provides limited financial data, specifically regarding stockholders' equity:
- Stockholders' Equity: $1,872,000 as of September 30, 2024.
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide clear values for these metrics.
Material Changes and Listing Deficiencies
The company faces two distinct delisting risks from Nasdaq:
- Bid Price Rule Violation: Since October 8, 2024, the company has been non-compliant with the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
- Stockholders' Equity Violation: On November 19, 2024, the company received notice of non-compliance with the $2.5 million minimum stockholders' equity requirement (Nasdaq Listing Rule 5550(b)(1)). The reported equity of $1.872 million falls below this threshold.
Outlook, Risks, and Management Commentary
Management has requested a hearing before the Nasdaq Hearings Panel to address these deficiencies. The company intends to present a plan to evidence compliance and request an extension of time to regain compliance. However, the filing explicitly states there is no assurance that the Panel will grant the request for continued listing or that the company will be able to meet the listing rules within any granted extension.
Investor Verification Checklist
- Verify the current status of the hearing before the Nasdaq Hearings Panel.
- Confirm the company's specific plan to raise stockholders' equity above $2.5 million.
- Monitor the stock's bid price to determine if it has recovered above the $1.00 threshold.
- Review subsequent filings for any updates on the delisting decision or extension grants.